MedTrace Logo

Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients

NCT06909357 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-05-14

No results posted yet for this study

Summary

Despite the deleterious impact of smoking upon cancer treatment outcomes, smoking prevalence remains alarmingly high among cancer patients. Thus, reducing smoking by cancer patients is a public health priority, but treatments to date have demonstrated limited efficacy. Mobile health (mHealth) interventions have the potential to improve treatment efficacy while also greatly extending reach. The goal of this infrastructure proposal is to build a resource to facilitate the creation of mHealth tools that address the tobacco treatment needs of cancer patients. This resource, which will be available to researchers throughout Florida, would fill a critical gap in mHealth capacity.

Conditions

  • Smoking Cessation

Interventions

OTHER

Quitline Treatment (QT)

Tobacco Free Florida Quitline. 10-week supply of Combination Nicotine Replacement Therapy (NRT).

OTHER

App-based Treatment (mHealth)

Fully automated digitally-delivered smoking cessation intervention targeted to cancer patients. 10-week supply of Combination Nicotine Replacement Therapy (NRT).

Sponsors & Collaborators

  • Florida Biomedical Research Program - James & Esther King

    collaborator UNKNOWN

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Damon Vidrine, DrPH · Moffitt Cancer Center

  • Vani Simmons, PhD · Moffitt Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-28
Primary Completion
2026-07-31
Completion
2027-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06909357 on ClinicalTrials.gov